Eribulin Mesylate and Generics
About Eribulin [Inhibitor of microtubule dynamics]
Eribulin mesylate is an antitubulin antimitotic agent with distinct microtubule end-binding properties that result in inhibition of microtubule dynamics in ways that differ from those of vinblastine and paclitaxel.
Eribulin Mesylate is the most complex synthetic drug today. Its synthesis involves as many as 65 steps, earning it the nickname “the Mount Everest of synthetic drugs.”
Eribulin Mesylate is a type of chemotherapy. Eribulin is indicated for the treatment of people with locally advanced or metastatic breast cancer, and for the treatment of adults with unresectable liposarcoma.
Commercial Products
| Attributes | RD code | Brand Name | Approved | Owner | Area | WebSite |
|---|---|---|---|---|---|---|
| Originator | J9179 | Halaven® | 2010 | Eisai | USA | eisai.com |
| Biosimilar | ERI-001 | CNN：艾乐林® | 2024 | CHIATHAI TIANQIONG(CNN：正大天晴药业) | China | cttq.com |
| Biosimilar | APL-1702 | CNN：欧纳琳® | 2025 | Kindos Pharma(CNN：健进制药) | China | kindospharma.com |
| Biosimilar | H20233223 | CNN：®博立宁 | 2023 | BrightGene(CNN：博瑞制药) | China | bright-gene.com |
Business Cooperation
- You wish to purchase this product (Eribulin mesylate).
- Do you want to obtain the distribution rights for this product (Eribulin mesylate)?
- RxLibra has acquired the commercialization rights to Bright Gene’s products.
Related Products
-
About Non Small Cell Lung Carcinoma (NSCLC) Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC […]
-
About Acute Lymphocytic Leukemia（ALL） A type of leukemia (blood cancer) that comes on quickly and is fast growing. In acute […]
-
About Non Small Cell Lung Carcinoma (NSCLC) Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC […]
